Lifordi begins human trial of RA treatment after positive results
Biotechnology company Lifordi Immunotherapeutics has announced its Phase I study of rheumatoid arthritis (RA) treatment LFD-200 is underway, with positive initial results.
LFD-200 is a glucocorticoid antibody-drug conjugate (ADC) that delivers a potent steroid payload directly to immune cells, aiming to maintain the anti-inflammatory benefits of glucocorticoids while reducing systemic toxicity.
The double-blind, randomised SAD/MAD Phase I trial is being conducted with plans to enrol 176 participants across seven ex-US sites. The study will assess safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneous LFD-200.
The Phase I trial follows results, presented at the American College of Rheumatology (ACR), showing LFD-200 achieved sustained glucocorticoid (GC) exposures in immune cells of non-human primates (NHPs) for at least seven days. The candidate also suppressed proinflammatory cytokine expression without evidence of toxicity after 13 weekly, clinically relevant doses.
“In just over two years, we have taken LFD-200 from the lab to the clinic, which is a major accomplishment reflecting the execution by our team and support from our Board of Directors, Clinical Advisors, and industry partners,” said Arthur Tzianabos, President & Chief Executive Officer.
“We look forward to demonstrating how the data we have generated to date, which shows the immune-cell selectivity of our VISTA-targeted delivery approach, translates to first-in-human studies of LFD-200.”
LFD-200 must demonstrate safety in human patients
The key findings from trials in NHPs also show that LFD-200 dose-dependently reduced proinflammatory cytokines after ex vivo stimulation of whole blood and bone marrow. There was also no cortisol reduction observed at clinically relevant doses and no suppression of bone markers at clinically relevant doses.
“The ability to harness the anti-inflammatory effects of glucocorticoids while limiting systemic toxicities has been the ‘holy grail’ of autoimmune treatment for 75 years,” added Dr Matthew McClure, Chief Medical Officer of Lifordi.
“These data in NHPs show that a steroid can be delivered directly to immune cells with sustained exposures that deliver anti-inflammatory effects and have no impact on cortisol or bone biomarkers after 13 weekly clinically relevant doses of LFD-200.”
“Lifordi’s goal now is to determine if this is also true in the clinic, first by demonstrating that LFD-200 is safe and able to suppress inflammatory cytokines in HPs, followed by proof of mechanism in patients with RA, a prevalent disease where GCs are highly effective in almost all patients, but their use has been limited by toxicity.”
Bruno Quinney, Content Team, DDW
